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Increasing evidence suggests that extracellular Vpr could contribute to HIV pathogenesis through its effect on bystander cells. Soluble forms of
Vpr have been detected in the sera and cerebrospinal fluids of HIV-1-infected patients, and in vitro studies have implicated extracellular Vpr as an
effector of cellular responses, including G2 arrest, apoptosis and induction of cytokines and chemokines production, presumably through its ability
to transduce into multiple cell types. However, the mechanism underlying Vpr release from HIV-1-producing cells remains undefined and the
biological modifications that the extracellular protein may undergo are largely unknown. We provide evidence indicating that soluble forms of Vpr
are present in the extracellular medium of HIV-1-producing cells. Release of Vpr in the extracellular medium did not originate from decaying or
disrupted HIV-1 virions that package Vpr but rather appeared associated with HIV-1-mediated cytopathicity. Interestingly, Vpr was found to
undergo proteolytic processing at a very well conserved proprotein convertase (PC) cleavage site, R85QRR88↓, located within the functionally
important C-terminal arginine-rich domain of the protein. Vpr processing occurred extracellularly upon close contact to cells and most likely
involved a cell surface-associated PC. Consistently, PC inhibitors suppressed Vpr processing, while expression of extracellular matrix-associated
PC5 and PACE4 enhanced Vpr cleavage. PC-mediated processing of extracellular Vpr led to the production of a truncated Vpr product that was
defective for the induction of cell cycle arrest and apoptosis when expressed in human cells. Collectively, these results suggest that cell surface
processing of extracellular Vpr by PCs might regulate the levels of active soluble Vpr.
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HIV-1 encodes four accessory gene products –Vif, Vpr, Vpu
and Nef – which are thought to collectively manipulate host cell
biology in order to promote viral replication, persistence and
immune escape (reviewed in Emerman and Malim, 1998). One
of these accessory proteins, Vpr, is a 96 amino acid polypeptide
that is highly conserved both among the primate lentiviruses⁎ Corresponding author. Laboratory of Human Retrovirology, Institut de
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doi:10.1016/j.virol.2007.10.036HIV-1, HIV-2 and the simian immunodeficiency virus (Tristem
et al., 1998), supporting the notion that it plays an important role
during viral infection in vivo. Indeed, deletion of vpr and the
related vpx genes in simian immunodeficiency virus (SIV)
severely compromises virus burden and disease progression in
experimentally infected monkeys (Gibbs et al., 1995; Hirsch
et al., 1998). Despite its small size, Vpr induces multiple effects
in host cells in culture that may contribute to the phenotypic
effects observed in vivo (reviewed in Andersen and Planelles,
2005; Sherman et al., 2002a). First, Vpr has been shown to act
early in viral infection as a facilitator of HIV-1 preintegration
complex (PIC) entry through the limiting nuclear pore (Hein-
zinger et al., 1994; Popov et al., 1998). This activity is thought
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in nondividing cells, most notably in terminally differentiated
macrophages (Nitahara-Kasahara et al., 2007; Vodicka et al.,
1998). Consistent with this function, Vpr is packaged in re-
latively large amounts into viral particles through an interaction
with the carboxy-terminal of the p6 late domain of the Pr55gag
polyprotein precursor (Lu et al., 1995), contains nuclear tar-
geting sequences (Jenkins et al., 2001; Nitahara-Kasahara et al.,
2007; Sherman et al., 2001) and is present in PICs (Popov et al.,
1998). Second, expression of Vpr was reported to induce cell
cycle arrest in G2 by recruiting the DDB1-CUL4 VPRBPE3
ubiquitin ligase complex (Belzile et al., 2007; Hrecka et al.,
2007; Le Rouzic et al., 2007; Schrofelbauer et al., 2007; Wen
et al., 2007) and by activating the ATR (for Ataxia-Te-
langiectasia mutated and Rad3-related) checkpoint signaling
pathway, a signaling event that is normally part of the cell
response system to DNA damage and DNA replication stress
(Roshal et al., 2003). Such arrested cells were shown to
ultimately die as a result of apoptosis (Andersen et al., 2006;
Zhu et al., 2001). Finally, Vpr was also reported to act as a
transcriptional activator of the HIV-1 LTR as well as host cell
genes (Cohen et al., 1990; Kino et al., 2002; Muthumani et al.,
2006; Sherman et al., 2000).
Interestingly, beside being found in virions and in cells, Vpr
and Vpr cleavage products have been shown to exist as free
molecules in the plasma and the cerebrospinal fluids of HIV-1-
infected patients (Hoshino et al., 2007 ; Levy et al., 1994),
indicating that Vpr may be released extracellularly and may
exert its biological function beyond infected cells. In that
regard, extracellular recombinant Vpr was shown to transduce
cells in vitro, apparently via an energy- and receptor-inde-
pendent process (Henklein et al., 2000). Following cellular
uptake, recombinant Vpr was shown to retain the ability to
localize to the nucleus and to induce G2 arrest and apoptosis
(Henklein et al., 2000; Majumder et al., 2007; Sherman et al.,
2002b), thus raising the possibility that circulating forms of Vpr
observed in HIV-1-infected patients may exert biological ef-
fects on a broad range of host cells. Indeed, a large number of
studies have reported that treatment of cells with recombi-
nant Vpr or C-terminal Vpr fragments resulted in apoptosis
(Ayyavoo et al., 1997; Jacotot et al., 2000; Patel et al., 2000) and
cytotoxic effects (Huang et al., 2000; Piller et al., 1999) in a
variety of cell types. Furthermore, recombinant Vpr was also
shown to activate AP-1, JNK, and NF-κB in primary
macrophages (Varin et al., 2005), to impair cytokine production
in DC (Majumder et al., 2007) and to enhance replication in
chronically infected cells and in acutely infected primary
macrophages (Levy et al., 1995; Sherman et al., 2002b; Varin
et al., 2005). However, it has not yet been clearly established
how Vpr is released from HIV-1-infected cells. Furthermore, it
is unclear whether Vpr proteins released in the extracellular
milieu remain in a fully functional form.
In the present work, we provide evidence indicating that Vpr
is released in the extracellular milieu of HIV-1-producing cells
via a process that is most likely associated to HIV-1-mediated
cytopathicity. Interestingly, extracellular Vpr was cleaved by
cell surface-associated PCs at a site, R85QRR88↓, located withinthe functionally important C-terminal arginine-rich motif. The
resulting truncated Vpr product was found to be defective for
the induction of cell cycle arrest and apoptosis, suggesting that
cell surface processing of soluble Vpr by PC might represent a
mechanism to control the level of functionally active extra-
cellular Vpr during HIV-1 infection.
Results
HIV-1 Vpr and C-terminally cleaved products are detected in
the extracellular medium of HIV-1-producing cells
To determine whether Vpr can be detected in the extra-
cellular medium of HIV-1-producing cells, we initially trans-
fected human embryonic kidney (HEK) 293T cells with a
proviral construct (HxBruBH10.R+) expressing Vpr in cis or
with a Vpr-defective provirus (HxBruBH10.R+) complemented
in trans with an expressor plasmid encoding Vpr. Forty hours
post-transfection, cells were isolated by low-speed centrifuga-
tion while cell-free culture supernatants were fractionated by
ultracentrifugation to separate viral particles from virus-free
extracellular medium. The presence of native Vpr was analyzed
in HIV-1-producing cells, pelleted virions and virus-free ex-
tracellular medium as described in Materials and methods. As
shown in Fig. 1A, Vpr was detected as a single band of
approximately 16 kDa in lysates from Vpr+ HIV-1-producing
cells (Fig. 1A upper panel, lanes 3–4) as well as in lysates from
Vpr+ HIV-1 virions (Fig. 1A upper panel, lanes 7–8). Inte-
restingly, upon more sensitive immunoprecipitation/western
blot (IP/WB) analysis of cell lysates, a discrete band of lower
molecular weight reacting specifically with murine anti-Vpr
monoclonal antibodies (mAb) 9F2 was detected in addition to
native Vpr regardless of whether Vpr was expressed in cis or in
trans (Fig. 1A lower panel, lanes 3–4). Importantly, Vpr as
well as a fast migrating Vpr-related band was detected in the
virus-free extracellular medium of Vpr+ HIV-1-producing cells
by IP/WB analysis (Fig. 1A lower panel, lanes 7–8). In that
regard, it is interesting to note that the levels of fast and slow
migrating Vpr species were inverted in the extracellular me-
dium as compared to cell lysates (Fig. 1A lower panel, compare
lanes 3–4 to lanes 7–8).
To increase the sensitivity of Vpr immunodetection and to
analyze further Vpr release and possible processing, we con-
structed proviral (HxBruBH10.3HAR+) and expression (SV
CMV 3HA-Vpr) plasmids encoding a Vpr protein containing
hemagglutinin (HA) epitope tags fused to the protein N-ter-
minus (3HA-Vpr). The HxBruBH10.3HAR+ provirus was still
able to replicate and produce infectious virus in Jurkat T cell
even though the C-terminus of Vif had to be truncated in the
process of engineering the construct (data not shown).
Experiments similar to the one described in Fig. 1A led to
essentially the same observations with, however, a drastic in-
crease in sensitivity of Vpr species immunodetection (Fig. 1B).
Both slow and fast migrating forms of Vpr were detected in cell
and viral lysates as well as in extracellular medium from
HxBruBH10.3HAR+-producing cells (Fig. 1B upper and lower
panels, lanes 3 and 8). The fact that the fast migrating Vpr band
Fig. 1. HIV-1 Vpr and cleaved products are found in the extracellular medium of HIV-1-producing cells. (A) Native Vpr and cleaved products are detected in the
extracellular medium of HIV-1-producing 293T cells. 293T cells were mock-transfected (lanes 1 and 5) or transfected with HxBruBH10.R− (lanes 2 and 6) or
HxBruBH10.R− with SV CMV Vpr (lanes 3 and 7), or the HxBruBH10.R+ provirus (lanes 4 and 8). Forty hours post-transfection, cells, pelleted virus particles and
virus-free extracellular medium were isolated, lysed and analyzed for the presence of native Vpr directly by western blot (upper panel) or by IP/WB (lower panel).
Samples corresponding to 5% of the original crude cell (lanes 1–4) and viral (lanes 5–8) lysates were analyzed for the presence of Vpr and CA by western blot using
murine anti-Vpr mAb 9F2 and CA mAb, respectively (upper panels). In parallel, cell lysates (50% of total cell lysates) (lanes 1–4) and virus-free extracellular medium
(50% of total medium recovered) (lanes 5–8) were immunoprecipitated (IP) with rabbit anti-Vpr pAb and immunocomplexes analyzed by western blot using anti-Vpr
mAb 9F2 (lower panel). (B) Extracellular release of Vpr and C-terminally cleaved products requires expression of viral proteins and is independent of Vpr virion
incorporation. 293T cells were mock-transfected (lanes 1 and 6) or transfected with HxBruBH10.R− (lanes 2 and 7) or HxBruBH10.3HAR+ (lanes 3 and 8) or
HxBruBH10.3HAR+/p6 (1–17) (lanes 4 and 9), or SV CMV 3HA-Vpr (lanes 5 and 10). Forty hours post-transfection, cells, pelleted virus particles and virus-free
extracellular medium were isolated as described. Levels of HA-tagged-Vpr (3HA-Vpr) and CAwere determined in equivalent proportion of cell and viral lysates by
direct western blot using anti-CA or anti-HAmAb (upper panel). In addition, the presence of 3HA-Vpr in cell lysates and virus-free extracellular medium was analyzed
by IP/WB using anti-HA mAb (lower panel). (C) Cleaved Vpr is associated to the external surface of HIV-1-producing cells. 293T cells transfected with the indicated
proviral constructs or expression plasmids were extensively washed with PBS 40 h post-transfection prior to a 10-min treatment with 0.25% trypsin. Following
addition of 5 ml DMEM supplemented with 10% FCS to stop trypsin digestion, cells were extensively washed with PBS and lysed in NP40 lysis buffer. The presence
of 3HA-Vpr and cleaved products in cell lysates was analyzed by western blot using anti-HA mAb.
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gested that full-length Vpr undergoes processing at a putative
cleavage site located at the Vpr C-terminus since the 3HA tags
were fused at the N-terminal-end of the protein. To examine
how Vpr products were released extracellularly, we analyzed
Vpr release in cell cultures transfected with either the p6-
defective proviral construct, HxBruBH10.3HAR+/p6 (1–17),
which is unable to efficiently package Vpr into virions
(Checroune et al., 1995) or with an expression plasmid en-
coding 3HA-Vpr only (SV CMV 3HA-Vpr). Even though the
p6-defective virus was unable to efficiently incorporate Vpr
(Fig. 1B upper panel, compare lanes 8 and 9), we could still
detect large amounts of forms of Vpr in the extracellular me-dium (Fig. 1B lower panel, compare lanes 8 and 9), thus in-
dicating that extracellular Vpr does not primarily originate from
disrupted or decaying viral particles. Interestingly, expression of
Vpr alone did not lead to extracellular release of Vpr nor to
efficient Vpr processing (Fig. 1B upper panel, lane 5 and lower
panel lanes 5 and 10). In fact, co-expression of proviral con-
structs encoding Gag, Pol Vif, Tat and Rev was found to be
necessary and sufficient to detect release of soluble Vpr in
the extracellular medium (data not shown). As described for
native Vpr in Fig. 1A, the ratio of full-length 3HA-Vpr/cleaved
Vpr was inverted in cell lysates and extracellular medium from
HIV-1-producing 293T cells (Fig. 1B lower panel, compare
lanes 8–9 to lanes 3–4). To examine whether the C-terminally
Fig. 2. Vpr and C-terminal cleaved products are detected in the extracellular
medium of HIV-1-infected Jurkat T cell and human PBMC cultures. (A) Jurkat T
cells were mock-transfected (lanes 1 and 4) or transfected with HxBruBH10.R−
(lanes 2 and 5) or HxBruBH10.3HAR+ proviral constructs (lanes 3 and 6).
(B) PBMCsweremock-infected (lanes 1 and 4) or infected with HxBruBH10.R−
(lanes 2 and 5) or HxBruBH10.3HAR+ virus (lanes 3 and 6). The presence of
3HA-Vpr and 3HA-Vpr cleaved products in infected cells, viral lysates or virus-
free extracellular medium was determined 4 days post-infection for infected
PBMCs and 8 days post-transfection the infected Jurkat T cell cultures.
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intracellularly or were externally associated to cells, we treated
HxBruBH10.3HAR+-transfected 293T cells with 0.25% trypsin
prior to lysis and 3HA-Vpr detection by western blot. Fig. 1C
clearly reveals that proteolytic treatment of cells with trypsin
prior to lysis drastically decreased detection of the fast Vpr
migrating band while keeping levels of full-length Vpr intact
(Fig. 1C, compare lanes 4 and 3), thus indicating that truncated
Vpr products associated with cells are located on the external
surface. Moreover, these results suggest that Vpr undergoes
processing at its C-terminus extracellularly.
Finally, to ensure that these observations were reproducible
in the context of infected CD4+ T cells, we monitored the
presence of extracellular forms of Vpr in infected Jurkat T cell
cultures in which viral infection was let to spread over an 8-day
period as well as in HIV-1-infected peripheral blood mono-
nuclear cells (PBMCs). As shown in Fig. 2, results of these
experiments clearly reveal that Vpr as well as Vpr C-terminal
cleaved products are detected in the extracellular medium
during HIV-1 infection of Jurkat T cells (Fig. 2A lower panel,
lane 6) and primary PBMCs (Fig. 2B lower panel, lane 6).
Furthermore, as shown in HIV-1-producing 293T cells (Fig. 1),
some cleaved Vpr products were detected in association with
infected T cells (Fig. 2 lower panel A and B, lanes 3), most
probably representing extracellular forms of Vpr associated
with the cell surface.
Taken altogether, these results indicate that Vpr is released in
the extracellular medium of HIV-1-producing cells by a processthat requires expression of viral proteins but that is independent
of Vpr virion incorporation. Furthermore, released Vpr appears
to undergo processing at a putative cleavage site located within
the C-terminal domain of the protein.
Vpr is cleaved at a proprotein convertase processing site
located at the protein C-terminus
Having obtained evidence that Vpr undergoes processing at
the protein C-terminus, we next performed a deletion analysis in
order to map the putative cleavage site. Expression plasmids
encoding 3HA-Vpr harboring C-terminal deletions from amino
acid (aa) residue 79 to 96 (SV CMV 3HA-Vpr (1–78)) and from
residue 89 to 96 (SV CMV 3HA-Vpr (1–88)) were genera-
ted and used to trans-complement a Vpr-defective HxBruBH10.
R− provirus in transfection assays in 293T cells. As shown in
Fig. 3A, both 3HA-Vpr deletion mutants were expressed at
levels comparable to the wild type (Wt) 3HA-Vpr in transfected
cells (lanes 3–4) andwere efficiently released in the extracellular
medium (lanes 9–10), thus indicating that the C-terminal
domain of Vpr is dispensable for extracellular release. Im-
portantly, none of the extracellular Vpr deletion mutants dis-
played any detectable processing (Fig. 3A, lanes 9–10). Indeed,
processed 3HA-Vpr was found to migrate very closely to 3HA-
Vpr (1–88) (Fig. 3A, compare lanes 11 and 10) but slower than
3HA-Vpr (1–78) (Fig. 3A, compare lanes 11 and 9) indicating
that the putative Vpr processing site most probably lies between
residues 78 and 88 and very close to residue 88. Consistently, a
putative basic aa-specific PC cleavage site (R/K)-Xn-(R/K)↓
(n=0, 2, 4, 6) (Seidah and Chretien, 1999) was identified at Vpr
R85QRR88↓ positions using the Prop v.10b Propeptide cleavage
site prediction program (Duckert et al., 2004). Alignments of
HIV-1 Vpr from different viral isolates and clades show that the
putative P1 (R88) and P2 (R87) cleavage positions are very well
conserved, while the P4 (R85) position reveals a degree of
variation (Fig. 3B). To confirm whether this predicted PC
processing site was indeed functional, we selectively substituted
aa residues within the putative cleavage site using site-directed
mutagenesis. Given that the P4 position is important for pro-
cessing by furin while the P1 and P2 position are critical for PCs
in general (Thomas, 2002), we focused our mutagenesis on these
positions and generated 3HA-tagged Vpr mutants R85Q (this
amino acid substitution at the P4 position is often found in viral
isolates from clade B) and RR87/88AA (substitution mutations
at the P1 and P2 positions) (Fig. 3C). Both mutants were
efficiently expressed in HxBruBH10.R- provirus-cotransfected
293T cells and released in the extracellular medium (Fig. 3C,
lanes 3–4 and 9–10). Interestingly, while extracellular 3HA-
VprR85Q mutant exhibited a two-fold decrease in processing as
compared to Wt 3HA-Vpr (Fig. 3C, compare lanes 11 to 9),
processing of the double mutant RR87/88AAwas reduced by at
least six-fold (lane 10). These results strongly suggest that Vpr
contains a PC processing site, R85QRR88↓(V/A/G)R, within
the protein C-terminal arginine-rich region that is recognized by
a PC that is most probably distinct from furin. Furthermore, the
presence of hydrophobic aa residues such as valine, in some viral
strains, just following the cleavage site (i.e., at P1′) would be
Fig. 3. Vpr is cleaved at a PC processing site located within the arginine-rich C-terminal domain. (A) Deletion mapping of Vpr cleavage site. 293T cells were mock-
transfected (lanes 1 and 7) or transfected with HxBruBH10.R− (lanes 2 and 8), or cotransfected with HxBruBH10.R− and SV CMV 3HA-Vpr (1–78) (lanes 3 and 9),
SV CMV 3HA-Vpr (1–88) (lanes 4 and 10) or SV CMV 3HA-Vpr (lanes 5 and 11). As an additional control, cells were transfected with HxBruBH10.3HAR+ (lanes 6
and 12). Forty hours post-transfection, the presence of 3HA-Vpr and cleavage products was analyzed in cells and virus-free extracellular medium by IP/WB as
indicated. (B) Alignment of HIV-1 Vpr putative proprotein cleavage sites from different HIV-1 subtypes. The consensus Vpr aa sequences between amino acid residue
80 and 90 are derived from the HIV sequence database, Los Alamos National Laboratory (http://hiv-web.lanl.gov/content/hiv%1Edb/mainpage.html). Predicted PC
processing site aa residues are underlined and their positions indicated above. (C) Mutagenic analysis of the putative Vpr PC cleavage site. 293T cells were mock-
transfected (lanes 1 and 7), or transfected with HxBruBH10.R− (lanes 2 and 8) or HxBruBH10.3HAR+ (lanes 6 and 12), or cotransfected with HxBruBH10.R−
provirus and SV CMV 3HA-Vpr R85Q (lanes 3 and 9), SV CMV 3HA-Vpr RR87/88AA (lanes 4 and 10) or SV CMV 3HA-Vpr (lanes 5 and 11). Forty hours post-
transfection, 3HA-Vpr expression and extracellular release were analyzed in cells and virus-free extracellular medium by IP/WB as indicated. (D) Analysis of
extracellular Vpr products by mass spectrometry. Soluble Vpr and cleavage products from virus-free extracellular medium of mock-transfected or HxBruBH10.R− or
HxBruBH10.3HAR+ transfected 293Tcell were immunopurified. Eluted proteins with molecular mass ranging from 10 to 22 kDa were then analyzed by SELDI-TOF-
MS using the Protein-Chip Reader (Ciphergen Biosystem Inc., Fremont, CA).
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and Chretien, 1999).
To further identify the exact Vpr cleavage site, we im-
munopurified extracellular forms of 3HA-Vpr from virus-free
cell culture supernatant of HxBruBH10.3HAR+ provirus-
transfected 293T cells by immunoprecipitation using anti-HA
mAb and analyzed the molecular mass (MM) of proteins eluted
from the immunocomplexes by SELDI-TOF (surface-enhanced
laser desorption/ionization time-of-flight) mass spectrometry
(Ciphergen Biosystem Inc., Fremont, CA). Data of Fig. 3D
reveal the presence of two specific peaks of isolated proteins.
The first peak was found to correspond to a protein having a
molecular mass 16189.6 Da, which is indeed very close to the
predicted molecular mass of full-length 3HA-Vpr (theoretical
MM: 16166.0 Da). The second peak consisted of a mix of
proteins having MM ranging from 15355.6 to 15034.6 Da,
which are indeed very close to the predicted MM for of 3HA-
Vpr (1–88) (theoretical MM 15365.6 Da) and 3HA-Vpr (1–86)
(theoretical MM: 15054.4 Da), respectively.
Taken altogether, the results obtained by mutagenesis and
mass spectrometry are consistent with a sequential proteolysisprocess of Vpr. First, the protein is likely cleaved at a PC
processing site located at position 85–88, R85Q RR88↓, to lead
Vpr cleavage product 1–88. Then, the two terminal arginine
residues are most probably removed by a basic-aa specific
carboxypeptidases, such as carboxypeptidase D (CPD) (Fricker
and Leiter, 1999), thus leading to fully processed Vpr (1–86).
Proprotein convertases mediate extracellular HIV-1 Vpr
processing
To determine if PCs have an exclusive role in extracellular Vpr
processing, 293T cells were cotransfected with HxBru-
BH10.3HAR+ and expression plasmids encoding the protein-
based PC inhibitors α1-PDX or Spn4A (Fig. 4A). α1-PDX,
which is an α1-antitrypsin variant serine protease inhibi-
tor (serpin), contains the minimal consensus furin cleavage site
(R-I-P-R) in its reactive site loop and functions as a suicide
substrate inhibitor of PCs, including furin, PC5, PC3 and PACE4
(Jean et al., 1998; Thomas, 2002; Tsuji et al., 1999). Likewise,
Spn4A is a secretory pathway serpin from Drosophila melano-
gaster that contains a consensus furin cleavage site, R-R-K-R, in
Fig. 4. Proprotein convertases mediate HIV-1 Vpr processing. (A) Extracellular Vpr processing is inhibited by PCs inhibitors α1-PDX and Spn4A. 293T cells were
mock-transfected (lanes 1 and 8), or transfected with HxBruBH10.R− (lanes 2 and 9) or HxBruBH10.3HAR+ (lanes 3 and 10), or cotransfected with 10 μg of
HxBruBH10.3HAR+ and 1 μg of pIR v5 empty vector (lanes 4 and 11) or pIR PDX+v5 (lanes 5 and 12), or SV CMVexPA control vector (lanes 6 and 13), or pShuttle
CMV Spn4A (lanes 7 and 14). Forty hours post-transfection, the presence of 3HA-Vpr products was analyzed in cells and virus-free supernatants by IP/WB as
indicated. (B) Extracellular Vpr processing is inhibited by the PC inhibitor dec-RVKR-cmk. 293T cells were mock-transfected (lanes 1 and 5), or transfected with
either HxBruBH10.R− (lanes 2 and 6) or HxBruBH10.3HAR+ (lanes 3–4 and 7–8). Two days later, culture media were replaced with fresh medium and cells were
cultured for 7 h in presence (lanes 4 and 8) or in absence (lanes 1–3 and 5–7) of 10 μM dec-RVKR-cmk. 3HA-Vpr and cleaved products levels were analyzed in cell
lysates and virus-free extracellular medium by IP/WB as indicated (left panel). Vpr processing efficiency was analyzed by quantitating the density of each Vpr-related
band using an AGFA Duoscan T1200 scanner. Densitometric analysis of WB results was performed with Image Quant 5.0 from Molecular Dynamics. Vpr processing
efficiency is expressed as the percentage of cleaved-Vpr over total Vpr products in the extracellular medium. (C) PC5A and PACE4 expression increases Vpr
processing in different cell lines. Hela-CCR5, COS-1 and 293T cells were mock-transfected (lanes 1 and 7) or transfected with HxBruBH10.R− (lanes 2 and 8) or
cotransfected with HxBruBH10.3HAR+ and pIR v5 empty vector (lanes 3 and 9) or pIR mPC5A+v5 (lanes 4 and 10) or pIR hFurin FL (lanes 5 and 11) or pIR
hPACE4+v5 (lanes 6 and 12). Forty hours post-transfection, levels of 3HA-Vpr products were analyzed in cells and virus-free supernatants as indicated.
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PC2 by a slow-binding mechanism characteristic of serpin
molecules and forms kinetically trapped SDS-stable complex
with each enzyme (Richer et al., 2004). Fig. 4A reveals that
extracellular Vpr processing was significantly reduced in cells
expressing α1-PDX or Spn4A as compared to control cells
expressing empty vectors (compare lanes 12 and 11, and lanes 14
and 13). Interestingly, Spn4A appeared to have a more potent
inhibitory effect on extracellular Vpr processing than α1-PDX in
several reproducible experiments. To ensure that these inhibitory
effects were specific, we analyzed the processing of HIV-1
envelope gp160 precursor, a known substrate of furin (Thomas,
2002), in cell lysates from the same cell transfectants. As
expected, gp160 processing was inhibited in cells expressing α1-
PDX or Spn4A, with α1-PDX showing a more potent inhibition
of gp160 processing than Spn4A (data not shown). In a second
approach, HxBruBH10.3HAR+ provirus-transfected 293T cells
were treated 40 h post-transfection for 7 h with 10 μM of themembrane soluble peptide PC inhibitor decanoyl-Arg-Val-Lys-
Arg-chloromethyl ketone (dec-RVKR-cmk) (Jean et al., 1998).
Processing of extracellular Vpr was specifically inhibited by at
least 6-fold in presence of 10 μM dec-RVKR-cmk (Fig. 4B, right
panel, compare lanes 8 and 7; left panel). The fact that both
protein-based (α1-PDX and Spn4A) and peptide-based (dec-
RVKR-cmk) PC inhibitors inhibited extracellular Vpr processing
strongly suggests that basic aa-specific PCs mediate extracellular
Vpr processing during HIV-1 infection.
We next investigated which widely expressed PCs associated
with the constitutive secretory pathway could mediate processing
of extracellular Vpr. Furin, PC5 and PACE4 were selected
because of their potential role in proteolytic processing of Env
gp160 during HIV-1 infection (Thomas, 2002), but more im-
portantly because of their presence at the cell surface as well as in
the extracellularmedium as enzymatically active shed forms (Koo
et al., 2006; Mayer et al., 2004; Tsuji et al., 2003). Plasmids
expressing human furin, mouse PC5A or human PACE4 were
Fig. 5. Vpr is processed extracellularly by a PC that is cell surface associated. (A) HIV-1 Vpr is processed in the extracellular medium. 293T cells were mock-
transfected (lane 1) or transfected with HxBruBH10.R− (lane 2) or HxBruBH10.3HAR+ (lanes 3–6). Two days later, media were replaced with fresh culture medium
and cells were further cultured for different intervals of time as indicated. Cells and virus-free culture media were then harvested at the indicated times and analyzed for
the presence of 3HA-Vpr as indicated. (B) Extracellular Vpr is efficiently processed by a cell surface-associated PC. Equivalent amounts (approximately 1 μg) of in
vitro translated Vpr were added to 293T cells (2×105/2 ml of culture media) or to cell-free conditioned media (2 ml) collected from 293T cell overnight cultures in
presence or absence of 10 μM dec-RVKR-cmk. Cell-free supernatants (upper panel) and conditioned media (lower panel) were collected at the indicated time intervals
and analyzed for the presence of 3HA-Vpr and cleavage products by IP/WB.
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including Hela-CCR5, COS-1 and 293T and 48 h post-trans-
fection, levels of 3HA-Vpr and cleaved products were analyzed in
cell lysates and virus-free extracellular medium bywestern blot or
IP/WB (Fig. 4C). When PC5A or PACE4 were co-expressed
with 3HA-Vpr-expressing virus, the level of fast migrating Vpr-
processed forms detected in the extracellular medium of all
transfected cell lines was significantly increased (Fig. 4C, com-
pare lanes 12 and 10 with lane 9). Interestingly, this increased
detection of Vpr processed forms in the extracellular mediumwas
also accompanied by a similar increase in the detection of cleaved
product externally associated with cells (Fig. 4C, compare lanes 6
and 4 with lane 3) as shown in Fig. 1C. In contrast, co-expression
of furin in HxBruBH10.3HAR+-producing cell lines had a
marginal effect on basal Vpr processing (Fig. 4C, compare lanes
11 and 9 as well as lanes 5 and 3). Overall, these results suggest
that proprotein convertases PC5 and PACE4 can efficiently
process extracellular Vpr.
Extracellular Vpr is processed by a PC that is cell
surface-associated
The fact that full-length Vpr is detected mainly intracellu-
larly while processed-Vpr is found primarily in the extracellular
medium suggests that Vpr proteolytic processing occurs
extracellularly—i.e. at the cell surface or in the extracellular
medium. To examine these possibilities, we first performed a
time course analysis of 3HA-Vpr release from HIV-1-producing
293T cells. Equal amounts of HxBruBH10.3HAR+ provirus-
transfected 293T cells plated in 6 wells-plate (106 cells/2 ml
media per well) were extensively washed 40 h post-transfection
and incubated with fresh culture medium. Over a 3-h period and
at different time intervals, the presence of 3HA-Vpr and clea-vage products was analyzed in cell and virus-free extracellular
medium by western blot and IP/WB as described in Materials
and methods. Under these conditions, Vpr was first released
out in the extracellular medium mostly as a full-length pro-
tein as illustrated by detection of full-length 3HA-Vpr as early
as 15 min post-culture medium change (Fig. 5A, lane 3). By
30 min, 3HA-Vpr cleavage products started being clearly
detected and by 3 h almost 50% of extracellular Vpr consisted
of Vpr processed products (Fig. 5A, lanes 4–6), thus providing
evidence that Vpr processing occurs extracellularly once full-
length Vpr has been released out of infected cells.
To characterize whether Vpr was processed by a PC at the
cell surface or in the extracellular medium, equivalent amounts
of exogenous in vitro translated 3HA-Vpr was added to 293T
cell or to conditioned media for various time intervals. As
shown in Fig. 5B (upper panel), addition of in vitro translated
3HA-Vpr to 293T cell culture led to processing of exogenous
3HA-Vpr in the cell supernatants starting at 6 h and reaching a
peak by 12 h post-incubation (compare lanes 2–5 to lane 1).
This processing was PC-specific since addition of 10 μM dec-
RVKR-cmk to the culture media reduced drastically the ac-
cumulation of Vpr cleavage products (Fig. 5B, compare lanes
6–9 to lanes 2–5). In contrast, only trace amount of Vpr pro-
cessing was detected upon addition of exogenous 3HA-Vpr to
293T conditioned medium (Fig. 5B lower panel, compare lanes
2–5 to lane 1). Importantly, this residual processing of Vpr in
conditioned medium was not affected by addition of PC in-
hibitor. Similar results were obtained when baculovirus-ex-
pressed recombinant Vpr was used in similar experiments (data
not shown). Taken together, these results suggest that Vpr
undergoes proteolytic processing extracellularly upon close
contact with cells, most likely by a PC that is predominantly
cell-surface associated.
Table 1
Effect of Vpr-processing on Vpr-mediated apoptosis
PI(+)/annexin V(−) (%) PI(+)/annexin V(+) (%)
SV CMV Vpr−/GFP 2.9±0.5 9.2±0.4
SV CMV Vpr (1–86)/GFP 3.2±0.3 9.6±1.3
SV CMV Vpr Wt/GFP 7.9±1.4 25.9±3.3
Fig. 6. Effect of processing on Vpr-mediated cell cycle arrest. (A) 293T cells were cotransfected with GFP-expressing plasmid (pQBI 25) and expression plasmids
encoding Wt Vpr, Vpr (1–86)-truncated mutant and Vpr R80A. Forty-eight hours post-transfection, cell-associated DNA content of GFP-expressing cells was
analyzed by PI staining and FACS analysis. The ability of Wt Vpr, Vpr (1–86) or Vpr R80A to induce G2 arrest was determined by calculating the G2/M:G1 ratio.
Similar results were obtained in 3 independent experiments. (B) Vpr levels in each cell transfectant were analyzed by western blot using murine anti-Vpr mAb 9F2.
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arrest and apoptosis
It was previously reported that exogenous Vpr can transduce
cells and cause G2 arrest and apoptosis in HeLa and CD4+ T
cells (Henklein et al., 2000; Sherman et al., 2002b). Despite all
of our attempts, we were unable to demonstrate that soluble Vpr
released in the extracellular medium of HIV-1-producing cells
could actually cause G2 arrest and apoptosis when transferred to
uninfected Jurkat target cells (data not shown). This lack of
detectable activity may be related to the diluted amounts of
protein in the extracellular medium and/or the efficient pro-
teolytic processing that is taking place extracellularly. To de-
termine whether fully processed Vpr present in the extracellular
medium retained its ability to induce G2 cell cycle arrest upon
transduction of bystander cells, we analyzed the effect of Vpr
(1–86) expression on the cell cycle. 293T cells were cotrans-
fected with a green fluorescent protein (GFP)-expressing con-
struct as well as with expression plasmids encoding Vpr (SV
CMV Vpr Wt) or fully processed Vpr (1–86) (SV CMV Vpr
(1–86) or the G2 arrest-defective mutant R80A (SV CMV Vpr
R80A) and the cell cycle profile of the GFP-positive cellpopulation was analyzed by flow cytometry 48 h post-trans-
fection as described in Materials and methods. As shown in
Fig. 6A, Vpr (1–86) was unable to induce a G2 cell cycle arrest
as compared to full-length Vpr (Vpr (1–86) G2/M:G1 ratio=0.4
versus 3.5 for Wt Vpr) even though both proteins were
expressed at similar levels (Fig. 6B). Indeed the degree of G2
arrest induced by Vpr (1–86) was similar to that of Vpr R80A, a
well characterized G2 arrest-defective Vpr mutant (Belzile
et al., 2007). Finally, to determine whether proteolytic pro-
cessing of Vpr could modulate Vpr-mediated apoptosis, HeLa
cells were transfected with plasmids co-expressing GFP and Wt
or truncated Vpr, and apoptosis was monitored by PI and
annexin V staining 48 h post-transfection. Results presented in
Table 1 reveal that truncated Vpr (1–86), in contrast to Wt Vpr,
was unable to induce apoptosis. In presence of Vpr (1–86)
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approximately 26% of cells were apoptotic in presence of Wt
Vpr. Indeed, the level of apoptotic cells detected in Vpr (1–86)-
expressing cells was similar to that obtained in control cells
(Vpr−). Overall, these results indicate that processing of Vpr at
aa residue 86 abolishes the ability of the protein to induce a G2
cell cycle arrest and mediate apoptosis.
Discussion
In this study, we provide evidence indicating that Vpr as well
as Vpr cleaved products are detected in the extracellular
medium of several cell lines, including HEK 293T, HeLa, COS-
1 and CD4+ Jurkat T cells, producing HIV-1 in vitro (Figs. 1,
2A and 4) as well as in HIV-1-infected primary PBMCs (Fig.
2B). Interestingly, Vpr expression alone, in the absence of any
other viral products, did not lead to efficient Vpr extracellular
release even though the protein has the ability to kill cell by
apoptosis (Andersen et al., 2006; Stewart et al., 1997).
Apparently, efficient Vpr release requires co-expression of
viral proteins suggesting that other viral components or/and host
cell responses may be necessary for Vpr extracellular release.
Since Vpr is primarily located in the nucleus when expressed
alone (Sherman et al., 2001), it is possible that expression of
other nucleocytoplasmic shuttling viral proteins such as the Gag
polyprotein precursor might be necessary to transport the pro-
tein in the cytosol near the plasma membrane. In that regard, it
was previously reported that during viral infection, Vpr was
redistributed from the nucleus to the cytosol and membrane
compartments by a process that was independent from its in-
teraction with the p6 domain of Gag (Jenkins et al., 2001). In
addition to nuclear export and transport near the plasma mem-
brane, HIV-1-mediated cytopathicity, including plasma mem-
brane disruptions due to viral egress (Fauci, 1988) or the
combined proapoptotic/toxic function of HIV-1 gene products
(Gougeon, 2003), might be necessary for release of Vpr in the
extracellular medium. Nevertheless, our data clearly reveal that
Vpr release in the extracellular medium does not rely on the
protein ability to be packaged into nascent viral particles since
extracellular Vpr was detected in culture infected with p6-
defective viral particles even though these do not package Vpr
(Fig. 1B); as such, extracellular Vpr originates most likely from
infected cells undergoing HIV-1-related cytopathicity rather
than from disrupted or decaying virions.
Our data also provide evidence that Vpr undergoes pro-
cessing extracellularly. Deletion mapping analysis is consistent
with Vpr processing occurring within the C-terminal arginine-
rich domain of the protein and specifically at a very well
conserved putative PC motif located at position R85QRR88
(Fig. 3A). Indeed, site-directed mutagenesis of this putative PC
processing site reveals that double mutations of the conserved
basic arginine residues located at the P1 and P2 position for
alanine (Vpr RR87/88AA) drastically reduced Vpr processing,
while substitution of the less conserved arginine residue for a
glutamine (R85Q) at the P4 position, attenuated Vpr processing
(Fig. 3C). These results indicate that the basic arginine residues
in the P1 and P2 position are critical for Vpr processing, whilethe arginine located in the P4 position is not essential but seems
to modulate the extent of Vpr processing. In this regard, it is
interesting to note that several Vpr alleles encoded by labo-
ratory-adapted strains such as LAI or HIV-1 primary isolates
from different clades contain a glutamine or a proline residue
instead of an arginine at that position (Fig. 3B), thus raising the
possibility that soluble Vpr encoded by these alleles might be
less prone to efficient cleavage. Evidence that Vpr is under-
going processing at this site is also supported by our mass
spectrometry analysis of extracellular Vpr species, which re-
vealed the presence of primarily two Vpr cleavage products
with predicted molecular mass corresponding to products
undergoing cleavage at positions 88 (Vpr 1–88) and 86 (Vpr
1–86) in addition to full-length Vpr (Fig. 3D). As it has been
previously reported that the last two basic aa residues of the
released N-terminal peptide generated upon PC cleavage are
generally removed by carboxypeptidases (Fricker and Leiter,
1999), our results are consistent with a Vpr processing oc-
curring at the conserved double arginine residues (R87R88) in
the P1 and P2 position, thus generating an 88-aa polypeptide
that subsequently undergoes a rapid trimming of the two basic
pair residues leading to an 86-aa fully processed Vpr product.
The fact that fully processed Vpr was shown to migrate slightly
faster than the Vpr (1–88) deletion mutant (Fig. 3A) supports
such a sequential proteolytic process.
Furthermore, our results reveal that Vpr is initially released
as a full-length protein and subsequently processed extracellu-
larly by cell surface PCs (Fig. 5). PCs belong to a family of
evolutionary conserved dibasic- and monobasic-specific Ca2+-
dependent subtilisin-like serine proteinases related to the yeast
kexin enzyme that constitute the major endoproteolytic
processing enzymes of the secretory pathway in mammals
(Seidah and Chretien, 1999; Steiner, 1998). Traditionally, PCs
have been shown to cleave their substrates intracellularly. This
is particularly true for furin, the best known member of the
protease family (Thomas, 2002). Furin is known to exist at the
cell surface while other PCs, such as PACE4 and PC5, are
known to be secreted and anchored in the extracellular matrix
(Nour et al., 2005; Tsuji et al., 2003) and are therefore presumed
to have extracellular substrates. The inhibition of extracellular
Vpr processing using PC inhibitors such as dec-RVKR-cmk or
serpins α1-PDX and Spn4A strongly suggests that PCs are
involved in Vpr processing (Figs. 4A–B). Furthermore,
transient co-expression of PCs in several HIV-1-producing
cell lines (293T, Hela and COS-1) reveals that PC5 and PACE4
efficiently processed extracellular Vpr, while furin expression
had only a marginal effect (Fig. 5C). These results are consistent
with the fact that mutation of the arginine residue at the P4
position of the processing site, a residue critical for processing
by furin (Thomas, 2002), was not essential for Vpr cleavage.
Our data suggest that PC5 and PACE4 might be involved in
extracellular Vpr processing. This is especially relevant since
these enzymes can tolerate an aliphatic residue (e.g., Val or Leu)
at P1′ just following the cleavage site, whereas furin does not
(Seidah and Chretien, 1999). Interestingly, PC5 is expressed in
freshly isolated human CD4 T-lymphocytes, the natural host
cells of HIV-1 (Decroly et al., 1996; Hallenberger et al., 1997).
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lymphocytes (PBL), it is highly expressed in lymphoid tissues
such as thymus, lymph node and spleen (Hallenberger et al.,
1997) and as such might be present at the cell surface of
bystander cells located in close proximity of HIV-1-producing
cells in vivo. However, we cannot rule out at this point that other
PCs displaying similar substrate specificity and cellular location
may also participate to Vpr processing in vivo.
We were unable to demonstrate that the levels of extracellular
Vpr released fromHIV-1-producing cells could actually cause G2
arrest and apoptosis when transferred to uninfected target T cells.
The absence of detectable activity may be due to the diluted
amounts of Vpr in the extracellular medium but might also result
from the efficient processing that undergoes upon contact of the
protein with target cells. Indeed, efficient processing of Vpr by
PCs generates a truncated Vpr (1–86) that is defective for G2 cell
cycle arrest and unable to induce apoptosis upon expression in
cells (Fig. 6 and Table 1). These findings raise the possibility that
processing of extracellular Vpr by cell-surface PCs, such as PC5
and PACE4, might indeed represent a host cell process to func-
tionally inactivate the cytostatic and cytotoxic activities of ex-
tracellular Vpr. In addition to inactivating Vpr-mediated G2
arrest and proapoptotic activities, processing of extracellular Vpr
C-terminal may also represent a mechanism to prevent or li-
mit the uptake of the protein by target cells. The carboxy-terminus
domain of Vpr contains six highly conserved arginine residues
between residues 73 and 96. This domain shows similarity with
those of arginine-rich protein transduction domains and may
explain the transducing properties of Vpr, including its ability to
cross the cell membrane lipid bilayer (Coeytaux et al., 2003;
Henklein et al., 2000; Sherman et al., 2002b). In fact, transduction
of exogenous protein has been shown to very often involve the
attachment of arginine-rich domain of proteins to membrane
HSPG (Melikov and Chernomordik, 2005; Richard et al., 2005).
Likewise, soluble Vpr may interact with membrane HSPG via its
C-terminal arginine-rich domain as a first step prior to interna-
lization as was reported for other transducing proteins (Melikov
and Chernomordik, 2005). Given that PCs such as PC5 and
PACE4 are located in the extracellular matrix, it is possible that
processing of extracellular Vpr may occur upon attachment of the
protein to HSPG. Processing of extracellular Vpr by PCs will
delete four of the six conserved arginine residues and as such is
likely to interfere with the transduction properties of the protein
(Sherman et al., 2002b). More studies will be required to analyze
soluble Vpr interactions with cell surface HSPG and its im-
plications in terms of protein cellular uptake. Importantly, additio-
nal studies using recombinant Vpr proteins will be needed to
directly demonstrate that the level of extracellular Vpr biological
activity correlates with the degree of protein processing.
It is interesting that Vpr is not the only HIV-transducing
protein undergoing processing by PCs. Extracellular Tat was
reported to be cleaved by furin (Tikhonov et al., 2004). Furin
processing did not affect the rates of N-terminal cleavage pro-
duct uptake and nuclear localization but greatly reduced the
protein transactivation activity. It is thought that furin process-
ing is a mechanism to inactivate extracellular Tat protein. Al-
though our results point towards a role of Vpr processing byPCs as a mean to inactivate Vpr, we cannot entirely rule-out that
soluble truncated Vpr (1–86) may still have other biological
activities and function important for HIV infection in vivo.
In conclusion, this study provides evidence that HIV-1 Vpr is
released in the extracellular milieu of HIV-producing cells where
it undergoes processing by cell surface PCs such as PC5 or
PACE4. PC processing of extracellular Vpr occurs at a very well
conserved processing site located in the C-terminal arginine-rich
domain of the protein and leads to the production of a truncated
Vpr product that is unable to induce G2 cell cycle arrest and
apoptosis. We propose that PC processing of extracellular Vpr
might represent a mechanism to inactivate soluble Vpr.
Materials and methods
Plasmids and proviral DNA constructs
The expression plasmid SV CMV 3HA-Vpr was construc-
ted by inserting three consecutive hemagglutinin tags (3HA) to
the N-terminus of Vpr in SV CMV Vpr WT (Yao et al., 1998)
using a two-steps PCR approach. The introduced 3HA tag
contains 49 amino acids (aa): MASVSYPYDVPDYASLGG-
PSSVSYPYDVPDYASLGGPSSVYPYDVPDYA (HA epitope
sequences are underlined). The single mutant 3HA-Vpr R85Q
and the doublemutant 3HA-RR87/88AAwere produced by PCR-
mutagenesis using SV CMV 3HA-Vpr as template. SV CMV
3HA-Vpr (1–88), (1–86) and (1–78) as well as SV CMV Vpr
(1–86) were generated by introducing premature stop codons at
aa position 88, 86 or 78 of Vpr using PCR-mutagenesis. The SV
CMV Vpr− and R80A constructs as well as the bi-cistronic
expressors SV CMV Vpr/GFP, Vpr−/GFP were described
previously (Hrimech et al., 1999). The SV CMV Vpr (1–86)/
GFP plasmid was constructed by inserting a BglII/DraIII
fragment from pQB25I (Quantum Biotechnologies, Montreal,
Que, Canada) encoding theGFP coding sequence preceded by the
cytomegalovirus (CMV) early promoter into the BamHI sites of
SV CMV Vpr (1–86). The pET21c 3HA-Vpr plasmid was
generated by subcloning a DNA fragment encoding 3HA-Vpr
from SV CMV 3HA-Vpr into pET21c (Novagen, Madison, WI,
USA). SVCMVexPAvectorwas previously described (Yao et al.,
1998). HxBruBH10.R+ (gag+-pol+-vif+-vpr+-tat+-rev+-vpu+-
env+-nef−) and Vpr-defective HxBruBH10.R− proviral con-
structs were generated by introducing a SalI/KpnI fragment
encoding Vpu from HxBH10 (Levesque et al., 2003) into HxBru
or HxBru R- (Yao et al., 1995). The HxBruBH10.3HAR+
proviral construct was derived from the HxBruBH10.R+
provirus. In the process of introducing the DNA fragment
encoding 3HA-Vpr, an NheI site was created at nucleotide
position 5140 (+1=start of Bru transcription initiation site) before
the Vpr ATG by PCR-mutagenesis. The creation of the NheI site
led to the introduction of a frameshift mutation at aa position 174
in the Vif open reading frame that resulted in a truncated Vif
protein. The proviral construct HxBruBH10.3HAR+/p6 (1–17)
encodes a truncated p6gag domain (premature stop codon at aa
17). It was generated by replacing an ApaI (nucleotide position
2011)–BstZ17I (nucleotide position 2967) DNA fragment from
HxBruBH10.3HAR+ by the corresponding fragment from
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plasmids pIR hfurin, pIR mPC5A+v5 and pIR hPACE4+v5
encoding human furin, murine PC5A and human PACE4,
respectively, were described previously (Bergeron et al., 2005).
Plasmid pIR-PDX-v5 encoding the PC inhibitorα1-PDX fused to
a v5 tag was described elsewhere (Bergeron et al., 2003), while
pShuttle CMV Spn4A encoding the PC inhibitor Spn4A fused to
a Flag tag was kindly provided by Dr. François Jean (Department
of Microbiology and Immunology, University of British
Columbia, Vancouver, Canada). All plasmid constructions were
analyzed and confirmed by automated DNA sequencing.
Cells and reagents
HEK 293T, Hela-CCR5 and COS-1 cells were maintained in
Dulbecco's Modified Eagle Medium (DMEM) supplemented
with 10% fetal calf serum (FCS). Jurkat T-lymphoid cells were
maintained in RPMI-1640 medium supplemented with 10%
FCS. PBMCs were isolated from volunteers by Ficoll–Paque
centrifugation as recommended by the manufacturer (Amer-
sham, Baie d'Urfé, Quebec, Canada). Cells were then cultured
in the presence of phytohemagglutinin-L (5 μg/ml) (Sigma-
Aldrich Canada Ltd, Oakville, Ontario, Canada) and interleukin
2 (IL-2) (20 U/ml) (Sigma-Aldrich) for 48 h to activate lym-
phocytes. Following activation, cells were washed with com-
plete media to remove lectins and maintained in RPMI plus
20% FCS supplemented with 20 U/ml of IL-2. All cells were
cultured at 37 °C under a 5% CO2 atmosphere. Anti-HA mAb
were produced from hybridoma 12CA5, while anti-V5 and anti-
Flag mAb (M2) were purchased from Invitrogen (San Diego,
CA, USA) and Sigma-Aldrich, respectively. The anti-Vpr mAb
9F12 directed against an epitope comprising aa 4–16 was
kindly provided by Dr. Jeffrey B. Kopp (Kidney Disease
Branch, National Institutes of Health, Bethesda, USA). Rabbit
anti-Vpr polyclonal antibodies (pAb) were previously described
(Yao et al., 1995). Anti-HIV-1 capsid (CA or p24) protein mAb
were produced from hybridoma HB9725 (ATCC; American
Type Culture Collection, Manassas, VA, USA) while anti-
gp120 mAb recognizing both gp120 and precursor gp160 were
obtained from the NIH AIDS Research and Reference Reagents
Program. The PC inhibitor dec-RVKR-cmk was purchased from
Bachem Bioscience Inc. (King of Prussia, PA, USA). A 10-mM
stock solution was prepared in DMSO and was further diluted in
tissue culture medium to give the required final concentration.
Transfection
293Tand COS-1 cells were transfected by the standard calcium
phosphate DNA precipitation method. For detection of extra-
cellular 3HA-Vpr, 106cells were either transfected with 10 μg of
3HA-Vpr proviral DNA plasmid or cotransfected with 10 μg of
Vpr-defective proviral DNA plasmid and 5 μg of 3HA-Vpr
expression vector. For native Vpr proteolytic processing detection,
293T (4×106cells) were either transfected with 40 μg of proviral
DNAplasmid or cotransfectedwith 40μg ofVpr-defective proviral
DNA plasmid and 20 μg of Vpr expression plasmid vector. Hela-
CCR5 cells (4×105 in 6 wells plate) were transfected with 4 μg of3HA-Vpr proviral DNA construct and 0.5 μg of PC expression
plasmids using Lipofectamine 2000 (Invitrogen, San Diego, CA,
USA) according to the manufacturer instructions.
Analysis of Vpr processing in HIV-1-producing cells,
extracellular medium and viral particles
Transfected or infected cells were separated from virion-
containing supernatants by low-speed centrifugation and lysed
in 1%NP40 lysis buffer (140 mMNaCl, 8 mMNa2HPO4, 2 mM
NaH2PO4, 1% NP40, 0.5% SDS, pH7.2) supplemented with a
protease inhibitor cocktail (Roche Diagnostics Canada, Laval,
Que, Canada). Vpr was immunoprecipitated from cell lysates
using anti-HA or anti-Vpr antibodies as described (Yao et al.,
1995). For detection of extracellular Vpr, 16 ml of culture
supernatants was first centrifuged at 2095×g for 10 min and then
passed through a 0.45-μm filter to eliminate cell debris. Viral
particles were separated from the extracellular medium by ultra
centrifugation onto a 20% sucrose cushion at 126087×g for
1.5 h. Eight milliliters of virus-free extracellular medium treated
with 5-fold concentrated NP-40 lysis buffer was immunopreci-
pitated with anti-HA or anti-Vpr antibodies as described (Yao
et al., 1995). Pelleted virus was lysed directly in 1% NP40 lysis
buffer. Cell and viral lysates as well as immunocomplexes
resulting from immunoprecipitations were separated by 14%
SDS–PAGE, transferred to a nitrocellulose membrane and
analyzed by western blotting using antibodies against HIV-1
capsid p24, HA or Vpr as described previously (Levesque et al.,
2003). Bound antibodies were revealed using the 3,3′-dia-
minobenzidine detection system, as recommended by the ma-
nufacturer (ICN Biomedicals, Irvine, CA, USA). For detection
of extracellular native Vpr, supersensitive Immobilon™ Wes-
tern Chemiluminescent HRP Substrate (Millipore, Billerica,
MA, USA) was used according to the manufacturer instructions.
Analysis of extracellular Vpr processing in HIV-1-infected
Jurkat T cells and human PBMCs
HIV-1-infected Jurkat T cells cultures were generated by
transfecting Jurkat T cells (4×106) with 20 μg of Vpr− or 3HA-
Vpr HIV-1 provirus using the DEAE-dextran method (Levesque
et al., 2003). Analysis of Vpr processing was conducted at the
peak of virus production (8 days post-transfection) as described
above. HIV-1 virus stocks were generated by transfection of
proviral constructs in 293T cells and titered by MAGI assay as
described previously (Levesque et al., 2003). PBMCs (5×106)
were infected at a multiplicity of infection (MOI) of 0.25 four
days post-activation as described before (Yao et al., 1998).
Analysis of Vpr processing was conducted 4 days post-infection
as described above.
Surface-enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF-MS) analysis
3HA-Vpr was isolated from virus-free culture supernatant of
HxBruBH10.3HAR+-transfected 293T cells by immunopreci-
pitation using anti-HA antibodies. 3HA-Vpr was eluted from
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trifluoroacetic acid (TFA). The 3HA-Vpr-containing eluate was
combined with a similar volume of binding buffer (100 mM
PBS and 0.5 M NaCl pH 7.0), applied onto a NP20 Protein-
Chip spot (Ciphergen Biosystems Inc., Fremont, CA, USA) and
incubated at room temperature for 20 min to dry. Unbound
samples on the chip spot were washed-off following three
washes of 5 min with binding buffer. The NP20 chip was then
rinsed with 20 μl of distilled H2O and air dried. A matrix
consisting of a saturated solution of 3,5-dimethoxy-4-hydro-
xycinnamic acid (SPA) in 50% acetonitrile and 0.5% TFA was
added to the chip surface before SELDI-TOF-MS analysis. The
SELDI-TOF-MS analysis was performed using a Ciphergen
Protein-Chip Reader (Ciphergen Biosystem Inc., Fremont, CA,
USA). Cytochrome c (12 kDa) was used as the molecular mass
calibrator.
In vitro translation
3HA-Vpr was in vitro translated from pET21c 3HA-Vpr
using the Active Pro™ In vitro translation kit (Ambion, Austin,
TX, USA) according to manufacturer instructions.
Cell cycle profiling and analysis of apoptosis
Cell cycle analysis was performed as described (Nishizawa
et al., 2000). Briefly, 293Tcells were cotransfected with 10 μg of
expression plasmids encoding Wt Vpr, truncated Vpr (1–86) or
Vpr R80A and 0.5 μg of GFP-expressing plasmids. Cells were
harvested 40 h later, fixed in 1% paraformaldehyde during
10 min and incubated in 70% ethanol for an additional 10 min.
Fixed cells were then treated with phosphate-buffered saline
(PBS) containing propidium iodine (PI) (50 μg/ml), RNase A
(50 μg/ml) and FCS (1%, vol/vol) for 60 min at room tem-
perature. The DNA content of GFP-positive cells was analyzed
on a FACScan flow cytometer using the Cell QUEST software
(Becton Dickinson, Franklin Lakes, NJ, USA). Relative num-
bers of cells in the G2/M and G1 phases of the cell cycle (G2/M:
G1 ratios) were calculated using the ModFit LT software (Verity
Software House, Topsham, ME, USA). Apoptotic cells were
detected using the Annexin V-Alexa Fluor 647 assay (Invitro-
gen, San Diego, CA, USA). Briefly, 40 h post-transfection
0.25×106 Hela cells were washed once with PBS and then
incubated for 20 min in annexin V binding buffer (2.5 μl of
Annexin V-Alexa Fluro 647 per ml, 10 mMHEPES–NaOH [pH
7.4], 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2
and 1 μg/ml of PI). Apoptotic cells, which stained positive for PI
and annexin V, were detected using a FACScalibur (Becton
Dickinson, Franklin Lakes, NJ, USA).
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